How to Clean Your Arteries: What Actually Works

No supplement, juice cleanse, or detox protocol will flush plaque out of your arteries the way a drain cleaner unclogs a pipe. But the idea that arterial plaque is permanent once it forms is also wrong. Under the right conditions, plaque can shrink, stabilize, and become far less likely to cause a heart attack or stroke. The distinction matters because the interventions with real evidence behind them look nothing like what most “artery cleansing” marketing promotes. The strategies that work target the biology driving plaque growth, and some of them can produce measurable regression within a year or two.

What Plaque Actually Is

Understanding what you’re trying to reverse helps explain why some approaches work and others don’t. Atherosclerosis starts when the inner lining of an artery gets damaged, often from high blood pressure, smoking, or high blood sugar. Once that lining is compromised, cholesterol-carrying particles, especially a modified form of LDL, slip into the arterial wall and get stuck there.¹ Those trapped particles oxidize, triggering an inflammatory chain reaction. Immune cells rush in, gorge on the oxidized fat, and become “foam cells” that pile up inside the artery wall.²

Over years, this accumulation grows into a plaque made of lipids, fibrous tissue, immune cells, and sometimes calcium.³ The danger isn’t just the narrowing of the artery. A plaque with a thin, fragile cap over a large fatty core can rupture, triggering a blood clot that blocks flow entirely. That’s how most heart attacks happen. So “cleaning” your arteries isn’t just about shrinking the plaque; it’s also about making whatever plaque remains less likely to rupture.

Intensive Statin Therapy Has the Strongest Evidence

If any intervention deserves to be called artery cleaning in a literal sense, it’s high-dose statin therapy. Statins don’t just slow plaque growth. At high doses, they can reverse it. A head-to-head trial comparing high-dose atorvastatin and rosuvastatin found that both drugs shrank plaque in the majority of patients. Rosuvastatin produced regression in about 69-71% of patients, and atorvastatin in about 63-65%, depending on the measurement used.⁴ These are patients whose coronary plaque physically got smaller over roughly two years on medication.

A meta-analysis of lipid-lowering therapy trials confirmed the pattern: high-intensity statin therapy drove the most consistent reductions in total plaque volume, while lower-intensity regimens didn’t produce a clear shrinkage signal.⁵ The relationship appears to be roughly dose-dependent: the lower you drive LDL cholesterol, the more plaque tends to regress. One interesting finding from pooled trial data is that women showed greater degrees of plaque regression than men on the same high-intensity statin regimens, especially when LDL cholesterol dropped to very low levels.⁶

The mechanism isn’t complicated: by dramatically lowering the concentration of LDL particles in the blood, statins cut off the supply of raw material that feeds plaque growth. They also have anti-inflammatory effects on the artery wall. But the key takeaway is that modest statin doses that bring LDL down a little aren’t enough for regression. You need the aggressive approach to see plaque actually shrink.

PCSK9 Inhibitors Push LDL Even Lower

For patients who can’t get LDL low enough on statins alone, or who can’t tolerate statins at all, a newer class of drugs offers additional firepower. PCSK9 inhibitors are injectable medications that can slash LDL cholesterol by more than half on top of what statins achieve. The GLAGOV trial showed that adding the PCSK9 inhibitor evolocumab to statin therapy produced an additional 1% reduction in percent atheroma volume compared to statin-plus-placebo, and shrank total plaque volume by about 5 mm³ more than statins alone.⁷ Those numbers sound small, but they reflect meaningful changes in the modifiable soft-plaque components, the fatty, necrotic tissue that makes a plaque dangerous.

A meta-analysis of randomized trials with PCSK9 inhibitors confirmed significant reductions in both percent atheroma volume and total atheroma volume, along with evidence that plaque composition shifted toward greater stability (thicker fibrous caps, less lipid-rich core).⁸ A critical finding from the GLAGOV data was that the relationship between lower LDL and greater plaque regression was linear all the way down to an LDL concentration of about 20 mg/dL, far below the traditional targets.⁷ This undercuts the old notion that there’s some floor below which further LDL reduction stops helping.

Targeting Inflammation Directly

Since inflammation drives plaque growth and instability, researchers have been testing anti-inflammatory drugs as a way to reduce cardiovascular events independent of cholesterol lowering. Colchicine, a cheap, old drug historically used for gout, has emerged as a genuine option. Clinical trials have shown that colchicine reduces cardiovascular events by roughly 23-31%, depending on whether patients had a recent heart attack or chronic coronary disease.⁹ It works by dampening the inflammatory signaling pathway that promotes plaque progression and rupture.

Colchicine’s effect is additive to statins, meaning it’s not doing the same thing by a different route. Statins lower cholesterol (with some anti-inflammatory benefits), while colchicine directly targets the inflammatory cascade. For people already on maximized lipid-lowering therapy who still have residual cardiovascular risk, this represents a genuinely different lever to pull. The FDA approved low-dose colchicine for cardiovascular use in 2023, making it one of the first inflammation-targeted drugs to enter mainstream heart disease management.

Diet Changes That Move the Needle

Dietary intervention is where the marketing noise is loudest and the evidence requires the most nuance. No single food will clean your arteries. But sustained dietary patterns can measurably slow, and in some cases partially reverse, plaque progression. The strongest data comes from the Mediterranean diet, which is rich in olive oil, fish, nuts, vegetables, and whole grains. In the CORDIOPREV trial, patients with existing coronary heart disease who followed a Mediterranean diet rich in extra-virgin olive oil for years showed reduced thickness of their carotid artery lining and smaller carotid plaques compared to those on a low-fat diet.¹⁰

A separate randomized trial tested an intensive lifestyle intervention combining plant-based diet, exercise, and stress management in patients with early-stage coronary disease. The intervention group saw a greater reduction in non-calcified plaque compared to controls, though overall plaque volume didn’t differ significantly between groups.¹¹ The non-calcified plaque component is the dangerous, rupture-prone part, so this matters even if the total volume didn’t budge much. The honest read on diet is this: it can meaningfully slow progression and improve plaque composition, but diet alone in most people won’t produce the dramatic regression seen with high-dose statins. It’s a foundational layer, not a standalone cure.

How Exercise Protects Artery Walls

Exercise benefits your arteries through a mechanism that has nothing to do with “flushing” or “scrubbing” plaque away. When you exercise, blood flow speeds up and exerts a frictional force called shear stress on the artery lining. That physical force triggers the lining cells to produce nitric oxide, a molecule that relaxes arteries, lowers local inflammation, and discourages clot formation.¹² In lab studies of human endothelial cells, exercise-level shear stress boosted the activation of the nitric-oxide-producing enzyme by about 57% compared to resting conditions.¹³

Regular training promotes an anti-inflammatory, antioxidant environment in the artery wall and stabilizes the structures that keep the endothelial lining intact.¹⁴ The effect is cumulative: repeated bouts of exercise train the endothelium to maintain better function between sessions. This is why sedentary people who start exercising show improved arterial function within weeks, even before any weight loss or cholesterol changes show up in bloodwork. Exercise won’t melt away a calcified plaque, but it can shift the balance from an artery wall that’s vulnerable to damage and clotting toward one that actively resists both.

Chelation Therapy and Supplements That Overpromise

EDTA chelation therapy is one of the most heavily marketed “artery cleaning” treatments in alternative medicine. The claim is that infusing a chemical chelating agent into the bloodstream dissolves calcium from plaques and flushes it away. The evidence doesn’t support this. A systematic review of chelation trials found that EDTA had no effect on any measured outcome in patients with ischemic heart disease compared to placebo. Both groups improved, but the improvement was unrelated to whether they received EDTA.¹⁵

The one study that complicated this picture was the TACT trial in 2013, which suggested a modest benefit specifically in patients with diabetes. But a follow-up trial, TACT2, designed to confirm that finding, failed to show any benefit.¹⁶ At this point, the best reading of the evidence is that chelation therapy doesn’t work for arterial plaque. The persistent appeal of chelation is understandable because the metaphor is so intuitive: dissolve the calcium, clear the blockage. But arterial calcification isn’t like limescale in a kettle. Calcium deposits in plaque are embedded in a complex biological matrix that a circulating chelating agent can’t selectively dismantle.

Vitamin K2 is another supplement that gets promoted as an artery cleaner. The biological rationale here is actually more interesting than chelation’s. Vitamin K2 activates a protein called matrix Gla protein, which inhibits the processes that deposit calcium in soft tissues like artery walls.¹⁷ In theory, adequate K2 helps keep calcium in bones and out of arteries.¹⁸ Some observational studies have linked higher K2 intake with lower rates of arterial calcification. But observational associations don’t prove that supplementing with K2 will reverse or prevent plaque in someone who already has it. Large randomized trials on K2 and hard cardiovascular endpoints are still lacking. It’s plausible enough that ensuring adequate K2 intake through fermented foods, cheese, or supplements isn’t a bad idea, but calling it artery cleaning goes well beyond what the data currently show.

Blood Pressure, Blood Sugar, and the Conditions That Feed Plaque

Plaque doesn’t grow in a vacuum. Uncontrolled high blood pressure mechanically stresses the artery lining, accelerating damage that lets cholesterol particles infiltrate the wall. High blood sugar, especially in type 2 diabetes, promotes both inflammation and the kind of endothelial dysfunction that makes plaques grow faster and become more unstable. Managing these conditions is therefore an indirect but powerful way to slow or halt plaque progression.

A newer class of diabetes drugs, SGLT2 inhibitors, has shown effects on arteries that go beyond sugar control. These medications improve endothelial function and reduce arterial stiffness through multiple mechanisms: lowering blood pressure, reducing body weight, decreasing inflammation, and pulling excess fluid from the body.¹⁹ A systematic review confirmed that several SGLT2 inhibitors significantly improved measures of blood vessel function and stiffness in people with diabetes.²⁰ These aren’t artery-cleaning drugs per se, but they address the metabolic environment that makes plaque formation so aggressive in diabetic patients.

Chronic Stress Is a Risk Factor People Overlook

Stress is usually mentioned as an afterthought in cardiovascular health conversations, but the evidence for its role in plaque instability is striking. Chronic stress causes endothelial injury, activates immune cells in the artery wall, and promotes the formation of the foam cells that make up the dangerous core of a plaque.²¹ In animal models, chronic intermittent mental stress led to larger coronary plaques, thinner fibrous caps, more macrophage infiltration, more heart attacks, and significantly lower survival rates compared to unstressed controls.²²

You can’t extrapolate mouse stress experiments directly to human office jobs, but the direction of evidence is consistent across human epidemiological studies as well: chronic psychological stress correlates with faster plaque progression and more cardiovascular events. The practical implication is that stress management isn’t just a feel-good recommendation. Sustained cortisol elevation, sympathetic nervous system overdrive, and the inflammatory state they produce actively undermine whatever other interventions you’re using to protect your arteries.

Your Gut Bacteria May Be Involved

An emerging line of research points to a molecule called TMAO (trimethylamine N-oxide) as a contributor to plaque formation and instability. Certain gut bacteria produce trimethylamine when you eat foods rich in choline, lecithin, or carnitine, which are concentrated in red meat, eggs, and some dairy. Your liver then converts that trimethylamine into TMAO, which circulates in the blood and appears to promote endothelial dysfunction, platelet activation, and inflammatory signaling in artery walls.²³

In human studies, higher blood levels of TMAO have been linked with substantially higher risks of heart attacks, strokes, and cardiovascular death. One study found that patients with the highest TMAO levels had roughly two to five times the risk of future cardiovascular events compared to those with the lowest levels, and this held up even after accounting for traditional risk factors like cholesterol and blood pressure.²⁴ The precise mechanisms are still being worked out, and it’s not clear yet whether TMAO is a causal driver or a marker of a broader metabolic state that promotes atherosclerosis.²⁵ There are no approved TMAO-lowering drugs yet, but the connection reinforces the evidence favoring plant-heavy diets and limiting red meat consumption for cardiovascular health.

Stents and Bypass Don’t “Clean” Arteries Either

If you’re picturing a stent or bypass surgery as a definitive artery cleaning, the reality is more complicated. These procedures physically open up blocked segments, but they don’t treat the underlying disease process happening throughout your arterial tree. For stable coronary artery disease, where you have significant plaque but aren’t having an acute heart attack, the evidence on whether stents help has been surprisingly ambiguous. A meta-analysis of randomized trials found that for stable disease, initial stent placement showed no advantage over medications alone for preventing death, heart attacks, or the need for later procedures.²⁶

The large ISCHEMIA trial and other landmark studies have reinforced a similar conclusion: for patients with chronic stable coronary disease whose symptoms are manageable, optimal medical therapy alone is a defensible, evidence-based strategy that performs comparably to revascularization on the outcomes patients care most about, like staying alive and avoiding heart attacks.²⁷ This isn’t an argument against stents or bypass in all cases. Acute heart attacks, unstable angina, and left main coronary artery blockages are situations where procedures save lives. But for the broader population of people with “clogged arteries” who are stable, the best approach is usually the medical and lifestyle strategy described above, not a procedure.

Experimental Approaches on the Horizon

Researchers are exploring several strategies aimed at actively pulling cholesterol back out of artery walls, which would be the closest thing to true plaque cleaning. One approach involves enhancing the body’s natural process of reverse cholesterol transport, where HDL particles extract cholesterol from cells in the artery wall and shuttle it to the liver for disposal. Synthetic HDL mimetics and nanoparticles have been designed to do this job more efficiently than natural HDL. In early human testing, one such compound, CER-001, was infused into patients and shown to target atherosclerotic plaques directly, raising blood levels of apolipoprotein A-I and boosting the blood’s capacity to pull cholesterol from cells.²⁸ Other experimental platforms include nanoparticles that can deliver anti-inflammatory drugs directly to the plaque, and modified red blood cells that act as cholesterol sinks.²⁹

None of these are available as treatments yet. The gap between proof-of-concept and approved therapy in cardiovascular medicine is long and littered with failures. But they represent a genuine shift in thinking, from slowing plaque growth to actively extracting its contents. If any of these pan out, the phrase “cleaning your arteries” might eventually describe an actual medical procedure rather than a marketing slogan for garlic supplements.